Poor infra to delay COVID-19 vaccination in rural PH | Inquirer Business

Poor infra to delay COVID-19 vaccination in rural PH

/ 04:07 AM February 24, 2021

Poor infrastructure and the lack of cold storage facilities in the countryside will slow down the Philippines’ vaccination program to inoculate the entire population, the Asian Development Bank (ADB) said on Tuesday.

Citing earlier projections from the Economist Intelligence Unit (EIU), the ADB said in a report that it would take the Philippines up to the fourth quarter of 2023 to finish vaccinating the rest of its population after prioritizing vulnerable groups.

Compared to other Asean (Assocation of Southeast Asian Nations) countries, vaccination rollout in the Philippines would lag behind Singapore’s plan to finish inoculation by the fourth quarter of this year, Vietnam’s by the second quarter of next year, Brunei Darussalam and Thailand in the third quarter of 2022, Malaysia in the second quarter of 2023 and Indonesia by the third quarter of 2023.

ADVERTISEMENT

The Philippines’ timetable to vaccinate the entire population is the same as in Bangladesh, Nepal, Samoa and Tonga.

FEATURED STORIES

Poorer Southeast Asian countries like Cambodia, Laos, Myanmar and Timor-Leste may take up to 2024 or beyond to vaccinate all of their respective populations.

Lack of storage

“In the Philippines, it is difficult to access rural and remote communities due to unpredictable weather, security concerns and poor infrastructure. Inadequate provision of transportation has seen health-care workers resort to hiring private motorcycles and pump boats to deliver and administer vaccines,” the ADB brief titled “Getting Ready for the COVID-19 Vaccine Rollout” read.

“Refrigerators in health centers in rural areas are subject to intermittent power supply with no backup power source. Vaccine wastage also occurs owing to a lack of skilled personnel,” it added.

Citing 2020 data by logistics firm DHL, the ADB said cold-chain logistics in the Philippines scored four out of five as the highest score in terms of preparedness for facilities that required conventional temperature requirements or about 2-8 degrees Celsius, which AstraZeneca vaccines, for instance, needed as storage temperature.

But in case vaccines needed stringent temperature requirements of as low as negative 80 degrees Celsius, cold-chain facilities in the Philippines scored only two out of five. Pfizer vaccines, in particular, needed to be stored at as low as negative 70 degrees Celsius.

In an earlier report, the ADB said the Philippines faced constraints in vaccine financing as “the government estimates that P82.5 billion (about $1.7 billion) will be required to provide vaccines to approximately 55 percent of the country’s population—still short of its plan to vaccinate all Filipinos by 2023.”

ADVERTISEMENT

Citing the vaccine allocation plan prepared by the Department of Health (DOH), the ADB had said the Philippine government targeted to vaccinate 25.35 million Filipinos in 2021, 44.63 million in 2022, and 41.77 million in 2023, since by that time the Philippines would have a total population of 112.89 million.

BEN O. DE VERA
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Business, COVID-19, COVID-19 vaccination

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.